利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

47 条记录 (耗时 0.031 秒)

    Tissue plasminogen activator having zymogenic or fibrin specific properties
    7.
    发明授权
    Tissue plasminogen activator having zymogenic or fibrin specific properties 失效
    组织纤溶酶原激活剂具有酶原或纤维蛋白特异性

    公开(公告)号：US5405771A

    公开(公告)日：1995-04-11

    申请号：US178945

    申请日：1994-01-07

    申请人： Stephen Anderson ,  William F. Bennett ,  David Botstein ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

    发明人： Stephen Anderson ,  William F. Bennett ,  David Botstein ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

    IPC分类号： A61K38/00 ,  A61K38/48 ,  C07H21/04 ,  C12N1/21 ,  C12N5/10 ,  C12N9/64 ,  C12N9/72 ,  C12N15/55 ,  C12N15/58 ,  C12N15/63 ,  C12N15/70 ,  C12N15/86

    CPC分类号： C12N9/6456 ,  A61K38/00

    摘要： Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

    摘要翻译： 制备组织纤溶酶原激活剂（t-PA）酶原和变体，包括t-PA的纤维蛋白溶解活性变体，其在t-PA的蛋白酶结构域内的位置具有氨基酸改变，与相应的野生型t- PA，与相应的野生型t-PA相比，其改变使纤维蛋白溶酶原纤维蛋白原和/或纤维蛋白（或血浆凝块）存在下的变形酶原。 可以制备编码酶原和变体的DNA序列，以及掺入DNA序列的表达载体和用表达载体转化的宿主细胞。 酶原和变体可用于药物制剂中以治疗血管疾病或病症或预防纤维蛋白沉积或哺乳动物中的粘附形成或重新形成。

    Tissue plasminogen activator having zymognic or fibrin specific properties
    9.
    发明授权
    Tissue plasminogen activator having zymognic or fibrin specific properties 失效
    组织纤维蛋白溶酶原激活物具有酶学或纤维蛋白特异性

    公开(公告)号：US5821105A

    公开(公告)日：1998-10-13

    申请号：US733124

    申请日：1996-10-17

    申请人： Stephen Anderson ,  William F. Bennett ,  David Botstkin ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

    发明人： Stephen Anderson ,  William F. Bennett ,  David Botstkin ,  Deborah L. Higgins ,  Nicholas F. Paoni ,  Mark J. Zoller

    IPC分类号： A61K38/00 ,  A61K38/48 ,  C07H21/04 ,  C12N1/21 ,  C12N5/10 ,  C12N9/64 ,  C12N9/72 ,  C12N15/55 ,  C12N15/58 ,  C12N15/63 ,  C12N15/70 ,  C12N15/86

    CPC分类号： C12N9/6456 ,  A61K38/00

    摘要： Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.

    摘要翻译： 制备组织纤溶酶原激活剂（t-PA）酶原和变体，包括t-PA的纤维蛋白溶解活性变体，其在t-PA的蛋白酶结构域内的位置具有氨基酸改变，与相应的野生型t- PA，与相应的野生型t-PA相比，其改变使纤维蛋白溶酶原纤维蛋白原和/或纤维蛋白（或血浆凝块）存在下的变形酶原。 可以制备编码酶原和变体的DNA序列，以及掺入DNA序列的表达载体和用表达载体转化的宿主细胞。 酶原和变体可用于药物制剂中以治疗血管疾病或病症或预防纤维蛋白沉积或哺乳动物中的粘附形成或重新形成。